Novo Nordisk A/s

This study will follow about 470 adults with type 2 diabetes who are starting oral semaglutide as part of their normal care. Researchers will track changes in blood sugar (HbA1c) and body weight over 5 to 7 months. The goal is to see how well the medication works when prescribed …

This study tests whether UBT251 is safe and effective for people who are overweight or have obesity. About 333 participants will receive either UBT251 or a placebo injection. The main goals are to check for side effects and measure weight change over time.

This early-stage trial tests a new medicine called NNC0581-0001 in 48 adults with fatty liver and suspected liver inflammation. Participants receive monthly injections for three months, either the drug or a placebo. The study lasts about 58 weeks and mainly checks safety and how …

This study is testing a new experimental medicine called NNC1679-0001 for type 2 diabetes. It is a very early (phase 1) trial to check if the drug is safe and how the body handles it. About 58 healthy volunteers and people with type 2 diabetes will receive a single injection of e…

This study is testing the safety of a medicine called eptacog alfa (NovoSeven) for women in India who have severe bleeding after giving birth. 64 women who do not respond to standard treatments will receive one or two doses of the drug. Researchers will monitor for blood clots, a…

This study tests a new medicine called CagriSema for weight loss in 2500 adults with obesity, some of whom also have type 2 diabetes. Participants receive either CagriSema or the existing drug semaglutide by chance. The goal is to see how much weight they lose and how safe the dr…

This program provides free daily injections of concizumab to people with congenital haemophilia who need better treatment. Participants will be monitored for safety and effectiveness over several years, with regular clinic visits and blood tests. The program continues until the d…

This study follows 630 people with type 1 diabetes in Japan who are already prescribed Awiqli, a once-weekly injection. Researchers will track side effects and blood sugar control over one year to see how the drug works in everyday life. The goal is to manage diabetes, not cure i…

This study looks at the long-term safety and effectiveness of etavopivat, an experimental medicine for sickle cell disease and thalassemia. It involves 480 adults, adolescents, and children who have already benefited from etavopivat in a previous study. Participants will continue…

This study tests a new medicine called etavopivat to see if it can reduce painful sickle cell crises (VOCs) in people aged 12 and older with sickle cell disease. About 408 participants will receive either etavopivat or a placebo for around 2 years. The goal is to confirm the drug…

This study tests an experimental oral medicine called Inno8 in 30 adults with hemophilia A. The goal is to see if it is safe and how the body processes it. Participants will take multiple doses over about 11 weeks. If successful, Inno8 could offer a more convenient way to control…

This study tests a potential new medicine called CDR132L in 200 people with heart failure and an enlarged heart. Participants receive either CDR132L or a placebo by IV every 4 weeks for 48 weeks. The goal is to see if the drug can improve heart structure and function.

This study tests a once-weekly injection called NNC0487-0111 in 300 adults with overweight or obesity and moderate-to-severe obstructive sleep apnea who use a breathing device. The goal is to see if the drug helps with weight loss and reduces breathing pauses during sleep. Partic…

This early-stage trial tests a new drug called NNC0497-0040 in healthy people, those with overweight or obesity, and people with type 1 diabetes who are also overweight. The goal is to see if the drug is safe and tolerable when given as a weekly injection. About 146 participants …

This study tests a new medicine called CDR132L in 200 people with a type of heart failure where the heart is stiff and thickened. The goal is to see if it can improve heart structure and function. Participants will receive either the study drug or a placebo by chance, and the stu…

This study tests a once-weekly injection called NNC0487-0111 in 300 adults with overweight or obesity and moderate-to-severe obstructive sleep apnea who do not use a breathing machine. The goal is to see if the drug helps with weight loss and reduces sleep apnea events. Participa…

This study tests whether a new medicine called ziltivekimab can reduce fatty plaque buildup in heart arteries after a heart attack. About 332 participants will receive either the drug or a placebo for 15 months. The goal is to see if the drug helps control artery disease and prev…

This study tests a once-weekly injection called NNC0487-0111 in 630 adults who are overweight or obese and have type 2 diabetes. Participants receive either the active drug or a placebo for about a year. The main goal is to see how much weight they lose, with additional checks on…

This study tests a new monthly injection called ziltivekimab in 10,000 people who recently had a heart attack. The goal is to see if it can lower the risk of having another heart attack, a stroke, or dying from heart disease. Participants will receive either the study drug or a p…

This early-stage study tests a new medicine (NNC9733-0001) to see if it is safe and tolerable in healthy volunteers and people with type 2 diabetes. Participants receive either the study drug or a placebo as a single injection. The goal is to check for side effects and how the dr…

This study tests a new medicine called NNC4005-0001 to see if it is safe and tolerable for people with extra body weight and too much fat in the liver. About 60 adults will get either the medicine or a placebo (a dummy pill) just once. The study lasts about 7 to 8 months and focu…

This study looks at how three medicines—CagriSema, semaglutide, and cagrilintide—affect muscle health in 100 adults aged 50-70 with obesity and slightly high blood sugar. Participants will receive one of the drugs or a placebo for up to 15 months. The goal is to understand how th…

This study tests whether a monthly injection called ziltivekimab can reduce heart failure-related deaths, hospitalizations, and urgent visits in people with heart failure and signs of inflammation. About 5,600 participants will receive either the drug or a placebo for up to 4 yea…

This study tests a new once-weekly injection, NNC0487-0111, for weight loss in 1150 adults with obesity. Participants receive either the drug or a placebo. The main goal is to see how much body weight they lose over time.

This study tests a new once-weekly injection called NNC0662-0419 for people with type 2 diabetes. About 270 adults will receive either the new drug, an approved drug (semaglutide), or a placebo to see how well it controls blood sugar and affects weight. The goal is to find the be…

This study tests if a new insulin that is injected just once a week works as well as daily insulin shots to control blood sugar in people with type 2 diabetes. About 586 adults who have never used insulin before will take either the weekly insulin or a standard daily insulin for …

This early-stage study tests an experimental drug, NNC4004-0002, in 60 adults with high uric acid levels but no symptoms. The main goal is to check safety and how the body handles a single injection. Participants receive either the drug or a placebo (saline) by chance. The study …

This study compares the experimental drug CagriSema (cagrilintide and semaglutide) to a calorie-reduced diet in 80 adults with obesity. It measures how each approach changes the body's energy use, like sleeping metabolic rate. The study lasts about 1.5 years, and all participants…

This study tests a new weekly injection (NNC0519-0130) in 465 adults with chronic kidney disease, with or without type 2 diabetes, who are also overweight or obese. The goal is to see if the drug safely improves kidney function compared to an existing medicine (semaglutide) or a …

This early-stage study tests how a new medicine, NNC0487-0111, affects insulin sensitivity and pancreas function in adults with type 2 diabetes. About 80 participants will receive either the study drug or a placebo. The goal is to see if the drug can help the body use insulin bet…

This study tests an experimental drug, NNC6019-0001, to see if it can lower the risk of heart-related death and hospital stays in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a disease that stiffens the heart. About 1,280 adults will be randomly assigned to receive…

This study tests whether a new medicine called NNC0487-0111, given as a weekly injection, is safe and effective for weight loss in adults with obesity. About 600 participants will receive either the active drug or a placebo (dummy injection) for comparison. The main goal is to me…

This study compares a new insulin that is injected once a week (insulin icodec) to a standard daily insulin (insulin glargine) in about 877 adults with type 1 diabetes. The goal is to see if the weekly insulin controls blood sugar just as well as the daily one. Participants will …

This study tests whether two new drugs, CagriSema and cagrilintide, can help children and adolescents with overweight or obesity lose weight. About 460 participants will receive either the study drugs, an existing drug (semaglutide), or a placebo. The main study lasts about 1.5 y…

This Phase 3 trial tests whether a once-weekly injection called NNC0487-0111 can help people with overweight or obesity and knee osteoarthritis lose weight and feel less pain. About 400 adults will receive either the drug or a placebo for several weeks. Researchers will measure c…

This early-stage trial is testing whether combining two experimental weight loss drugs—cagrilintide and a GIP receptor agonist—causes fewer stomach side effects like nausea and vomiting compared to taking cagrilintide alone. About 100 women who are overweight or obese will receiv…

This study tests a new medicine called ziltivekimab in 680 adults with heart failure and signs of inflammation. Participants will receive either the drug or a placebo for up to 16 months. The goal is to see if the drug improves heart failure symptoms and physical function, like b…

This early-stage study tests a new drug called NNC0537-1482 in 36 adults with heart failure. The main goal is to check if the drug is safe and how the body processes it. Participants are randomly assigned to receive either the drug or a placebo for up to 64 days. This research he…

This study tests a medicine called cagrilintide to see how it affects appetite and how much people eat. About 120 adults with overweight or obesity will receive either the drug or a placebo for around 30 weeks. The goal is to measure changes in total energy intake from meals and …

This early-stage study tests a new medicine, NNC6989-0001, for safety and tolerability in 96 healthy adults who are overweight or have obesity. Participants receive either the drug or a placebo by chance. The goal is to check for side effects and how the drug moves through the bo…

This study tests a new once-weekly injection (NNC0487-0111) in 400 adults with overweight or obesity and knee osteoarthritis. The goal is to see if it helps with weight loss and reduces knee pain compared to a placebo. Participants are randomly assigned to receive either the acti…

This early-stage study tests whether a once-weekly injection called NNC0487-0111 can lower how much people with obesity eat and reduce their appetite. About 120 adults will receive either the drug or a placebo for several months. The goal is to see if the treatment changes energy…

This early-stage study is for people with a heart condition called ATTR-CM, caused by abnormal protein buildup in the heart. Researchers are testing a new antibody, coramitug, to see how well it targets and helps remove these protein clumps. The study uses special imaging to trac…

This early-stage study is testing whether a new weekly injection called NNC0662-0419 changes how birth control pills and a common painkiller work in the body. Researchers will measure drug levels in the blood and stomach emptying in 45 women who cannot become pregnant and have ov…

This study looks at how long you need to fast and whether temporarily stopping GLP-1 medications (like liraglutide or semaglutide) affects how much food stays in your stomach. It involves 75 people with obesity who are already taking these drugs. The goal is to understand stomach…

This study looks at medical records of 400 adults aged 40-70 in Southeast Asia who were recently diagnosed with type 2 diabetes. The goal is to understand their heart disease risk factors, like blood pressure and cholesterol, at the time of diagnosis and during the first year. No…

This study will look at medical records of about 900 male children and adults with hemophilia A in Iraq to see how the clotting medicine turoctocog alfa is used in daily care. The goal is to understand bleeding rates and treatment patterns, but the study does not change or interf…

This study follows up on people who already received the experimental obesity drug INV-347 in an earlier study. No new medication is given. Researchers will track side effects and measure how long the drug stays in the body. The goal is to better understand the drug's long-term s…

This study tests a new medicine called Inno8 for hemophilia A. Researchers want to see how eating and drinking before and after taking the pill changes how much medicine gets into the blood. 80 healthy men aged 18-45 will take one dose after fasting, then wait different times bef…